OneSource Specialty Pharma Q1 FY27 Share Price & Earnings Call Analysis
- Market cap
- ₹18,000 Cr
- ROE
- -1.09%
- Price to sales
- 11.66
- Debt to equity
- 0.22
- 52W high / low
- ₹1,878 / ₹1,114
- Sales growth (5Y)
- 131.48%
- EBITDA margin
- 21.97%
- Net profit margin
- -4.50%
- Promoter holding
- 30.48%
- Sales (last year)
- ₹1,543 Cr
Incorporated in 2007, OneSource Specialty Pharma Ltd is in the research, development, manufacture and commercialisation of bio logical drug products in various injectable formats. It also offers end-to-end CDMO services across all phases of pre-clinical and clinical development and commercial supply of biologics[1]
Guidance scorecard · Q1 FY27 call
What OneSource Specialty Pharma Ltd's management guided
and where it ranks in Pharmaceuticals & Biotechnology
Pharmaceuticals & Biotechnology
RevenueQ1 FY27 call
40%+- Strong visibility on order book and capacity utilization through FY27 and FY28, supporting revenue growth.
- Capacity expansions: New sterile lines coming online this quarter and end of FY27, tripling sterile days by FY28 to 675 days, enabling higher volumes.
- Expansion in drug-device combination, biologics (including animal health and biosimilars), soft gelatin capsules, and injectables to drive growth beyond FY28.
- Biologics contracts with large global players expected to contribute commercial revenues from FY29 onwards.
- Soft gelatin capacity fully utilized with new greenfield facility planned to support growth.
- Injectable business adding new capabilities (pre-filled syringes, lyophilization) to boost sales.
- Addition of new customers enabled by increased capacity; supply constraints easing.
2 more points from OneSource Specialty Pharma Ltd's call on revenue
Create a free account to keep reading this call
MarginsQ1 FY27 call
FlatSee what OneSource Specialty Pharma Ltd said on margins — free account, 30 seconds.
CapexQ1 FY27 call
Planned- OneSource Specialty Pharma has committed approximately 80% of a planned US$100 million capex primarily for drug-device combination (DDC) capacity expansion.
- No significant additional capex planned for the current year beyond the balance 20% of the $100 million.
- Future biologics capacity expansion will require additional capex, but expected to be significantly lower than DDC investments.
- New capacity additions for sterile injectable lines and lyophilization are underway, including a planned shutdown in H1 FY27 to expand injectable capacity.
2 more points from OneSource Specialty Pharma Ltd's call on capex
Create a free account to keep reading this call
FundraisingQ1 FY27 call
See what OneSource Specialty Pharma Ltd said on fundraising — free account, 30 seconds.
Order bookQ1 FY27 call
Rising- The company has strong visibility on its order book and capacity utilization through FY27 and towards FY28.
- Drug-device combination segment has very clear demand with customers in Canada, India, and emerging markets, supporting robust order book.
- Biologics business shows significant traction with new contracts and a strong funnel expected to convert in coming quarters.
- Soft gelatin and injectable businesses are filling capacity with new customers onboarding.
- They have enough capacity to meet existing demand and plan new capacity additions from this quarter.
2 more points from OneSource Specialty Pharma Ltd's call on the order book
Create a free account to keep reading this call
Ranges are what management guided for revenue growth and margins on the latest earnings call. Not investment advice, and not a forecast of returns.
Potential multibaggers · Q2 FY27
Potential multibaggers in Pharmaceuticals & Biotechnology
on management's own guidance
- Strong growth2
- Strong growth1
- 3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Peers
Pharmaceuticals & Biotechnology companies ranked on guidance
| # | Company | Revenue guided | Margin guided | Market cap | P/E |
|---|---|---|---|---|---|
| 1 | 40%+ | Up 2%+ | ₹556 Cr | 22.1 | |
| 2 | 40%+ | Up 0–2% | ₹215 Cr | 22.2 | |
| 3 | OneSource Speci.This stock | 40%+ | Flat | ₹16,144 Cr | — |
| 4 | 40%+ | Flat | ₹6,072 Cr | 48.0 | |
| 5 | 40%+ | Flat | ₹40 Cr | — | |
| 6 | 20–40% | Up 2%+ | ₹50,220 Cr | 43.8 |
Sign up free to see every company in the sector ranking and track OneSource Specialty Pharma Ltd.
Pro shows every company guiding 40%+ revenue growth →Full Pharmaceuticals & Biotechnology rankingFinancials of OneSource Specialty Pharma Ltd
Quarterly Results, Profit & Loss, Balance Sheet, Cash Flows, and Ratios are shown below as separate sections.
Shareholder Pattern
OneSource Specialty Pharma Ltd
Shareholding breakup across reporting periods.
| Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 | |
|---|---|---|---|---|---|---|---|---|
| Promoters + | 37.76% | 34.25% | 29.78% | 29.77% | 29.93% | 30.48% | 30.48% | 30.47% |
| FIIs + | 17.44% | 18.54% | 18.69% | 19.39% | 19.24% | 17.50% | 19.19% | 19.45% |
| DIIs + | 12.56% | 18.03% | 18.09% | 18.48% | 18.80% | 20.61% | 23.37% | 24.20% |
| Public + | 32.24% | 29.17% | 33.42% | 32.34% | 32.01% | 31.40% | 26.95% | 25.86% |
| No. of Shareholders | 98,425 | 82,712 | 87,760 | 87,416 | 84,595 | 79,460 | 77,899 | 79,770 |
Pros & Cons
OneSource Specialty Pharma Ltd
Key positives and risks surfaced from the company insights section.
- Stock is trading at 3.04 times its book value
- Company has low interest coverage ratio.
- Company has a low return on equity of -2.63% over last 3 years.
- Promoters have pledged 38.8% of their holding.
- Company has high debtors of 177 days.
- Stock is trading at 3.04 times its book value
- Company has low interest coverage ratio.
- Company has a low return on equity of -2.63% over last 3 years.
- Promoters have pledged 38.8% of their holding.
- Company has high debtors of 177 days.
Financials of OneSource Specialty Pharma Ltd
Quarterly Results
Quarter-by-quarter operating performance
| Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales + | 34 | 56 | 73 | 292 | 334 | 393 | 426 | 327 | 376 | 290 | 428 | 449 | 516 |
| Expenses + | 72 | 67 | 76 | 228 | 257 | 251 | 243 | 239 | 269 | 273 | 336 | 326 | 353 |
| Operating Profit | -39 | -10 | -3 | 64 | 77 | 142 | 183 | 88 | 106 | 17 | 92 | 123 | 163 |
| OPM % | -114% | -19% | -3.8% | 22% | 23% | 36% | 43% | 27% | 28% | 6% | 21% | 27% | 32% |
| Other Income + | -32 | -74 | 3 | -1 | -1 | -94 | 2 | 2 | 3 | -2 | 2 | -0 | -1 |
| Interest | 25 | 26 | 20 | 42 | 45 | 46 | 33 | 27 | 34 | 38 | 23 | 31 | 35 |
| Depreciation | 18 | 20 | 20 | 68 | 68 | 69 | 68 | 68 | 70 | 70 | 72 | 72 | 75 |
| Profit before tax | -114 | -130 | -40 | -47 | -37 | -67 | 83 | -4 | 6 | -93 | -0 | 20 | 53 |
| Tax % | 0% | 0% | 0% | -88% | 12% | 4% | -19% | -96% | -83% | -5% | -1,630% | -23% | -9% |
| Net Profit + | -114 | -130 | -40 | -6 | -42 | -69 | 98 | -0 | 10 | -89 | 5 | 25 | 57 |
| EPS in Rs | -6.02 | 8.61 | -0.02 | 0.92 | -7.74 | 0.40 | 2.18 | 5.01 |
Financials of OneSource Specialty Pharma Ltd
Profit & Loss
Annual income statement trend
| Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM | |
|---|---|---|---|---|---|---|---|
| Sales + | 21 | 132 | 39 | 172 | 1,445 | 1,422 | 1,684 |
| Expenses + | 93 | 229 | 199 | 254 | 978 | 1,117 | 1,288 |
| Operating Profit | -71 | -97 | -161 | -82 | 467 | 304 | 396 |
| OPM % | -334% | -73% | -415% | -48% | 32% | 21% | 24% |
| Other Income + | 1 | 4 | -526 | -143 | -94 | 5 | -2 |
| Interest | 16 | 68 | 48 | 89 | 166 | 122 | 126 |
| Depreciation | 34 | 70 | 66 | 76 | 274 | 279 | 288 |
| Profit before tax | -121 | -231 | -800 | -391 | -68 | -92 | -20 |
| Tax % | 0% | -0% | 0% | 0% | -73% | -20% | |
| Net Profit + | -121 | -231 | -800 | -391 | -18 | -74 | -2 |
| EPS in Rs | -1.57 | -6.44 | -0.15 | ||||
| Dividend Payout % | 0% | 0% | 0% | 0% | 0% | 0% |
Financials of OneSource Specialty Pharma Ltd
Balance Sheet
Capital structure and asset base
| Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | Sep 2026 | |
|---|---|---|---|---|---|---|---|
| Equity Capital | 2 | 3 | 4 | 4 | 11 | 11 | 11 |
| Reserves | 774 | 1,009 | 781 | 392 | 5,869 | 5,820 | 5,909 |
| Borrowings + | 386 | 1,154 | 864 | 562 | 772 | 1,276 | 1,755 |
| Other Liabilities + | 96 | 276 | 365 | 468 | 1,005 | 1,197 | 910 |
| Total Liabilities | 1,258 | 2,442 | 2,015 | 1,426 | 7,657 | 8,304 | 8,586 |
| Fixed Assets + | 633 | 1,231 | 1,361 | 863 | 6,118 | 6,017 | 6,445 |
| CWIP | 431 | 490 | 334 | 188 | 218 | 529 | 141 |
| Investments | 0 | 0 | 4 | 20 | 16 | 16 | 17 |
| Other Assets + | 195 | 722 | 314 | 356 | 1,305 | 1,742 | 1,983 |
| Total Assets | 1,258 | 2,442 | 2,015 | 1,426 | 7,657 | 8,304 | 8,586 |
Financials of OneSource Specialty Pharma Ltd
Cash Flows
Operating, investing and financing cash movement
| Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|
| Cash from Operating Activity + | -118 | -416 | -163 | -107 | -68 | 9 |
| Cash from Investing Activity + | -207 | -692 | -68 | 511 | -201 | -495 |
| Cash from Financing Activity + | 381 | 1,162 | 118 | -391 | 412 | 359 |
| Net Cash Flow | 56 | 54 | -112 | 13 | 143 | -127 |
| Free Cash Flow | -325 | -1,071 | -207 | -171 | -196 | -561 |
| CFO/EBITDA Share of operating profit converting into cash: CFO (before tax) / Operating Profit | 164% | 430% | 108% | 130% | -13% | 6% |
Financials of OneSource Specialty Pharma Ltd
Ratios
Working capital efficiency and return ratios
| Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|
| Debtor Days | 38 | 65 | 36 | 117 | 105 | 177 |
| Inventory Days | 87 | 1,805 | 615 | 258 | 222 | 438 |
| Days Payable | 762 | 410 | 420 | 163 | 147 | 307 |
| Cash Conversion Cycle | -637 | 1,461 | 232 | 212 | 180 | 308 |
| Working Capital Days | -2,392 | -1,291 | -6,745 | -877 | -58 | -6 |
| ROCE % | -10% | -12% | -12% | 6% | 1% |
Guidance history
How OneSource Specialty Pharma Ltd's guidance has moved, call by call
| Call | Revenue | Margins | Capex | Fundraising | Order book |
|---|---|---|---|---|---|
| Q1 FY27 call → | 40%+ | Flat | Planned | — | Rising |
| Q4 FY26 call → | 20–40% | Up 2%+ | Planned | — | — |
| Q3 FY26 call → | 20–40% | Flat | Planned | Planned | Rising |
| Q2 FY26 call → | 20–40% | Flat | Planned | Planned | Rising |
What management guided on each call, newest first. Not investment advice, and not a forecast of returns.
Momentum score · price trend
21 out of 100 — Cooling
Over the past year its share price has done worse than most of the stocks we track.
| Period | Share price change | Better than … of 1,910 stocks |
|---|---|---|
| Last 12 months | −15.3% | 42% |
| Last 6 months | −9.7% | 37% |
| Last 3 months | −7.0% | 48% |
The price is 28.5% below its all-time high of ₹2,194 (27 Jun 2025). Stocks more than 20% below their peak have their score halved, so 42 became 21.
How we calculate it
“Better than 30%” means that over that period the share price did better than 30 out of every 100 stocks we track (1,910 Indian companies worth ₹500 Cr or more, with at least a year of prices).
The score weighs the longer periods more: 40% × 12-month + 40% × 6-month + 20% × 3-month. For OneSource Specialty Pharma Ltd: 0.4 × 42 + 0.4 × 37 + 0.2 × 48 = 42, halved to 21 because the price is more than 20% below its all-time high.
Strengthening is 70 and above, Steady 40 to 70, Cooling below 40. Scores are recalculated every night after the market closes.
Full methodology →This describes only how the share price has moved up to 29 Oct 2026, compared with other stocks. It says nothing about the business, and it is not a prediction, a price target or a recommendation to buy or sell.
Continue your research
What OneSource Specialty Pharma Ltd's management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- Lincoln Pharmaceuticals Ltd (Q2 FY27)
2,798.12 Lakhs increase (approximately 17.1% growth) . Key results statement takeaways from Lincoln Pharmaceuticals Ltd's Q2 FY27 results statement — and how it
- Alivus Life Sciences Ltd (Q2 FY27)
Q2 FY27 Revenue from Operations: ₹6,820 million, up 16.0% year-on-year (YoY). Key investor presentation takeaways from Alivus Life Sciences Ltd's Q2 FY27 invest
- Strides Pharma Science Ltd (Q2 FY27)
Q2FY27 Revenue: ₹14,297 million, up 17.1% YoY (Page 4, 15) . Key investor presentation takeaways from Strides Pharma Science Ltd's Q2 FY27 investor presentation
- Laurus Labs Ltd (Q2 FY27)
2Q FY27 Revenue:** ₹2,206 crore, up 33% year-on-year (Y-o-Y) and 9% quarter-on-quarter (Q-o-Q). Key investor presentation takeaways from Laurus Labs Ltd's Q2 FY